Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 17/20 | 1.00 |
| ▸ | CAMKK1 | Q8N5S9 | 4/20 | 1.00 |
| ▸ | SGK1 | O00141 | 3/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | SGK3 | Q96BR1 | 1/20 | 1.00 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 1.00 |
| ▸ | AXL | P30530 | 4/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk-650394 SCHEMBL30753539 | 1.00 | CAMKK2 (1.00) | CAMKK2CAMKK1SGK1AURKASGK3 | |
| Gsk-650394 SCHEMBL29368746 | 1.00 | CAMKK2 (1.00) | CAMKK2CAMKK1SGK1AURKASGK3 | |
| SCHEMBL3767383 | 0.81 | CAMKK2 (1.00) | CAMKK2CAMKK1SGK1AURKASGK3 | |
| SCHEMBL3768084 | 0.79 | CAMKK2 (1.00) | CAMKK2CAMKK1SGK1AURKASGK3 | |
| SCHEMBL3767167 | 0.79 | CAMKK2 (0.76) | CAMKK2CAMKK1SGK1AURKASGK3 | |
| SCHEMBL3762417 | 0.78 | CAMKK2 (0.74) | CAMKK2CAMKK1SGK1AURKASGK3 | |
| SCHEMBL3764354 | 0.78 | CAMKK2 (0.82) | CAMKK2CAMKK1SGK1AURKASGK3 | |
| SCHEMBL3766865 | 0.78 | CAMKK2 (1.00) | CAMKK2CAMKK1SGK1AURKASGK3 | |
| SCHEMBL3774587 | 0.77 | AXL (1.00) | CAMKK2SGK1AURKASGK2AXL | |
| SCHEMBL3759420 | 0.77 | AXL (1.00) | CAMKK2SGK1AURKASGK2AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228552-A9 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIVERSITY OF MASSACHUSETTS | 2024-07-11 | — | — | US | claimed |
| US-20240132551-A1 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIV MASSACHUSETTS (US) | 2024-04-25 | — | — | US | claimed |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | claimed |
| WO-2010049173-A1 | USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES | CENIX BIOSCIENCE GMBH (DE) | 2010-05-06 | — | — | WO | claimed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | claimed |
| EP-1828180-A1 | 1H-PYRROLO[2,3-BETA]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006063167-A1 | 1H-PYRROLO[2,3-B]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-15 | — | — | WO | claimed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| CN-119950724-A | Application of SGK1 as marker in tumor immunotherapy | 北京大学 | 2025-05-09 | — | — | CN | disclosed |
| CN-119818491-A | Application of SGK1 inhibitor in preparation of medicine for treating endometriosis | 中国福利会国际和平妇幼保健院 | 2025-04-15 | — | — | CN | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| US-20240228552-A9 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIVERSITY OF MASSACHUSETTS | 2024-07-11 | — | — | US | disclosed |
| WO-2018195450-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2018-10-25 | — | — | WO | disclosed |
| WO-2018156401-A1 | METHODS OF INHIBITING SERUM GLUCOCORTICOID INDUCED KINASE 1 (SGK1) AS A TREATMENT FOR SALT AND WATER BALANCE DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-08-30 | — | — | WO | disclosed |
| US-20170027915-A1 | TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTIONS USING ANTAGONISTS OF SGK1 ACTIVITY | UNIV JOHNS HOPKINS (US) | 2017-02-02 | — | — | US | disclosed |
| US-20140120111-A1 | TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTIONS USING ANTAGONISTS OF SGK1 ACTIVITY | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2014-05-01 | — | — | US | disclosed |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | disclosed |
| WO-2010049173-A1 | USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES | CENIX BIOSCIENCE GMBH (DE) | 2010-05-06 | — | — | WO | disclosed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027915-A1 | TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTIONS USING ANTAGONISTS OF SGK1 ACTIVITY | SGK1, SGK2, SGK3 | CAMKK2 381/4885CAMKK1 227/4885SGK1 1/4885 |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | SGK1, SGK2, SGK3 | CAMKK2 157/4885CAMKK1 97/4885SGK1 1/4885 |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | SGK1, SGK2, SGK3 | CAMKK2 125/4885CAMKK1 86/4885SGK1 1/4885 |
| US-20140120111-A1 | TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTIONS USING ANTAGONISTS OF SGK1 ACTIVITY | SGK1, SGK2, SGK3 | CAMKK2 381/4885CAMKK1 227/4885SGK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.